Erasca, Inc. (ERAS) income statement
ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.76−0.13 (-0.94%)
Close on Nov 18, 2026Market cap $4.81BP/E –Yield 0.00%
Erasca, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -33.3%
Financial strength
- Current ratio
- 8.29
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 126.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 13.30
- Dividend yield
- 0.00%
See a number that looks wrong?